GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype

The primary objectives of the Alzheimer's Prevention Registry GeneMatch program are to (1)
identify and characterize a large cohort of people who are interested in, and may be eligible
to participate in, current and future preclinical Alzheimer's disease research studies and
clinical trials based on their genetic background, and (2) provide information to these
individuals about research studies for which they may be eligible, based in part on their
genetic background. Cognitively unimpaired individuals age 55 to 75, inclusive, are eligible
to enroll in GeneMatch. GeneMatch will provide participants with a genetic sample kit (a
cheek swab) to test for a specific gene called apolipoproteins E (APOE). GeneMatch does not
disclose the results of the APOE test to participants. GeneMatch may use the APOE test
results to match participants to research studies. Participants are under no obligation to
pursue these study opportunities.

Inclusion Criteria:

- Age 55-75, inclusive

- Provide basic demographic, medical history, and contact information

- Consent to APOE genotyping without receiving results

- Live in the United States

Exclusion Criteria:

- Unable to comply with this project's protocol requirements

- Self-reported diagnosis of dementia or any other objective cognitive impairment
syndrome